Exploring the Role of Gut Microbiota in the Pathogenesis of Inflammatory Bowel Disease: Insights from Metagenomic Analysis

Fadlan Haris

doi:10.37899/mjdh.v1i1.22

Authors

Fadlan Haris Hasanuddin University

DOI:

https://doi.org/10.37899/mjdh.v1i1.22

Keywords:

Crohn's Disease, Gut Microbiota, Dysbiosis, Precision Medicine

Abstract

Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are chronic gastrointestinal disorders characterized by inflammation of the digestive tract. The gut microbiota plays a crucial role in IBD pathogenesis, yet its specific taxonomic and functional alterations remain to be fully elucidated. In this study, we conducted metagenomic sequencing analysis to investigate the composition and functionality of the gut microbiota in patients with CD or UC compared to healthy controls. Stool samples were collected from a cohort of patients with CD or UC and healthy controls, and metagenomic sequencing was performed using a state-of-the-art sequencing platform. Bioinformatics analysis revealed distinct taxonomic profiles and functional pathways in CD/UC patients compared to healthy controls. Our findings provide valuable insights into the microbial dysbiosis associated with IBD and highlight potential targets for therapeutic interventions aimed at restoring microbial homeostasis. This study contributes to advancing our understanding of the complex interplay between the gut microbiota and IBD pathophysiology, paving the way for personalized approaches to IBD management.

References

Aldars-Garcia, L., Chaparro, M., & Gisbert, J. P. (2021). Systematic review: the gut microbiome and its potential clinical application in inflammatory bowel disease. Microorganisms, 9(05), 977. https://doi.org/10.3390/microorganisms9050977

Alemany-Cosme, E., Sáez-González, E., Moret, I., Mateos, B., Iborra, M., Nos, P., ... & Beltrán, B. (2021). Oxidative stress in the pathogenesis of Crohn’s disease and the interconnection with immunological response, microbiota, external environmental factors, and epigenetics. Antioxidants, 10(1), 64. https://doi.org/10.3390/antiox10010064

Amoroso, C., Perillo, F., Strati, F., Fantini, M., Caprioli, F., & Facciotti, F. (2020). The role of gut microbiota biomodulators on mucosal immunity and intestinal inflammation. Cells, 9(5), 1234.

Caruso, R., Lo, B. C., & Núñez, G. (2020). Host–microbiota interactions in inflammatory bowel disease. Nature Reviews Immunology, 20(7), 411-426. https://doi.org/10.1038/s41577-019-0268-7

Eindor-Abarbanel, A., Healey, G. R., & Jacobson, K. (2021). Therapeutic advances in gut microbiome modulation in patients with inflammatory bowel disease from pediatrics to adulthood. International Journal of Molecular Sciences, 22(22), 12506. https://doi.org/10.3390/ijms222212506

Imdad, A., Pandit, N. G., Zaman, M., Minkoff, N. Z., Tanner-Smith, E. E., Gomez-Duarte, O. G., ... & Nicholson, M. R. (2023). Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews, (4).

Iyer, N., & Corr, S. C. (2021). Gut microbial metabolite-mediated regulation of the intestinal barrier in the pathogenesis of inflammatory bowel disease. Nutrients, 13(12), 4259. https://doi.org/10.3390/nu13124259

Jiang, P., Wu, S., Luo, Q., Zhao, X. M., & Chen, W. H. (2021). Metagenomic analysis of common intestinal diseases reveals relationships among microbial signatures and powers multidisease diagnostic models. Msystems, 6(3), 10-1128. https://doi.org/10.1093/ibd/izae082

Kedia, S., Ghosh, T. S., Jain, S., Desigamani, A., Kumar, A., Gupta, V., ... & Ahuja, V. (2021). Gut microbiome diversity in acute severe colitis is distinct from mild to moderate ulcerative colitis. Journal of gastroenterology and hepatology, 36(3), 731-739. https://doi.org/10.1111/jgh.15232

Kubinski, R., Djamen-Kepaou, J. Y., Zhanabaev, T., Hernandez-Garcia, A., Bauer, S., Hildebrand, F., ... & Martin, R. D. (2022). Benchmark of data processing methods and machine learning models for gut microbiome-based diagnosis of inflammatory bowel disease. Frontiers in Genetics, 13, 784397.

Liwinski, T., & Elinav, E. (2020). Harnessing the microbiota for therapeutic purposes. American Journal of Transplantation, 20(6), 1482-1488.

Loddo, I., & Romano, C. (2015). Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Frontiers in immunology, 6, 551. https://doi.org/10.3389/fimmu.2015.00551

Ma, Y., Zhang, Y., Jiang, H., Xiang, S., Zhao, Y., Xiao, M., ... & Xiao, Z. (2021). Metagenome analysis of intestinal bacteria in healthy people, patients with inflammatory bowel disease and colorectal cancer. Frontiers in cellular and infection microbiology, 11, 599734. https://doi.org/10.3389/fcimb.2021.599734

Manuc, T. E. M., Manuc, M. M., & Diculescu, M. M. (2016). Recent insights into the molecular pathogenesis of Crohn’s disease: a review of emerging therapeutic targets. Clinical and experimental gastroenterology, 59-70. https://doi.org/10.2147/ceg.s53381

Mishima, Y., & Sartor, R. B. (2020). Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases. Journal of gastroenterology, 55, 4-14. https://doi.org/10.1007/s00535-019-01618-1

Prasad, S., Cross, R. K., Monroe, M. B., Dolinger, M. T., Motte, R., Hong, S., ... & Selaru, F. M. (2024). Challenges in IBD research 2024: Novel technologies. Inflammatory bowel diseases, 30(Supplement_2), S30-S38. https://doi.org/10.1093/ibd/izae082

Shang, Z., Pai, L., & Patil, S. (2024). Unveiling the dynamics of gut microbial interactions: a review of dietary impact and precision nutrition in gastrointestinal health. Frontiers in Nutrition, 11, 1395664. https://doi.org/10.3389/fnut.2024.1395664

Sultan, S., El-Mowafy, M., Elgaml, A., & Mottawea, W. (2021). Metabolic influences of gut microbiota dysbiosis on inflammatory bowel disease. Frontiers in physiology, 12, 715506. https://doi.org/10.3389/fphys.2021.715506

Tie, Y., Huang, Y., Chen, R., Li, L., Chen, M., & Zhang, S. (2023). Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: pathophysiology and therapeutic targets. Gut Microbes, 15(2), 2265028. https://doi.org/10.1080/19490976.2023.2265028